<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03402165</url>
  </required_header>
  <id_info>
    <org_study_id>Alfafetoprotein</org_study_id>
    <nct_id>NCT03402165</nct_id>
  </id_info>
  <brief_title>Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C</brief_title>
  <official_title>Impact of Serum Alpha-fetoprotein Levels on the Response to Direct Antiviral Therapy in Egyptian Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic
      Hepatitis C
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Impact of Serum Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in
      Egyptian Patients with Chronic Hepatitis C
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with sustained virologic response</measure>
    <time_frame>6 months</time_frame>
    <description>The total number of patients with SVR in each group</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Normal Alfafetoprotein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild elevation of alfafetoprotein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High elevation of alfafetoprotein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir</intervention_name>
    <description>Response to DAAD's and developing HCC</description>
    <arm_group_label>Normal Alfafetoprotein</arm_group_label>
    <arm_group_label>Mild elevation of alfafetoprotein</arm_group_label>
    <arm_group_label>High elevation of alfafetoprotein</arm_group_label>
    <other_name>Sofaldy, Harvony</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV patients who will undergo treatment by direct acting antiviral agents.

        Exclusion Criteria:

          -  Patients with decompensated liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rehab Badawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Alboraie, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alazhar University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed el kassas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Helwan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, md</last_name>
    <phone>00201095159522</phone>
    <email>sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-elsalam, lecturer</last_name>
      <phone>00201000040794</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

